<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409341</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 2018-02</org_study_id>
    <nct_id>NCT03409341</nct_id>
  </id_info>
  <brief_title>Personalizing Immune Checkpoint Inhibitor Therapy</brief_title>
  <official_title>Personalizing Immune Checkpoint Inhibitor Therapy for Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holy Cross Hospital, Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holy Cross Hospital, Maryland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, observational study will evaluate whether vitro testing of tumor tissue and&#xD;
      white blood cells from patients with lung cancer who are being treated with immune checkpoint&#xD;
      inhibitors and other standard of care approaches, predicts clinical response to these agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Goal: The long-term goal of this study is to predict whether checkpoint inhibitors&#xD;
      will be effective in individual patients with solid tumors.&#xD;
&#xD;
      Objectives: In this pilot study to be conducted in ten subjects with lung cancer who are to&#xD;
      receive checkpoint inhibitors, we will use cellular and molecular techniques to characterize&#xD;
&#xD;
        -  tumor immunogenicity&#xD;
&#xD;
        -  anti-tumor T-cell response&#xD;
&#xD;
        -  effect of checkpoint inhibitors on antigen presentation and T-cell response, and&#xD;
&#xD;
        -  the tumor microenvironment&#xD;
&#xD;
      Planned enrollment:&#xD;
&#xD;
      • Ten subjects with lung cancer&#xD;
&#xD;
      Methods for Informed Consent:&#xD;
&#xD;
      Investigators will approach subjects for informed consent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumor immune response</measure>
    <time_frame>12 months</time_frame>
    <description>Tumor antigen presentation and anti-tumor T-cell response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>12 months for each subject</time_frame>
    <description>Clinical response is defined as 50% or greater decrease of the sum of the products of two-dimensional measurements of lesions on imaging within the first year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor microenvironment</measure>
    <time_frame>24 months total study duration</time_frame>
    <description>Tumor mutation burden from tumor genome landscape using DNA sequencing, tumor transcriptome with RNA sequencing, tumor infiltrating immune cells with flow cytometry</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer Stage IV</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and tumor tissue analysis, Clinical response.</intervention_name>
    <description>DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Peripheral blood samples will be used to evaluate immune cell anti-tumor response, and&#xD;
           DNA sequence.&#xD;
&#xD;
        2. A sample of tumor tissue excised for diagnostic biopsy will be used to evaluate tumor&#xD;
           immunogenicity, tumor transcriptome, tumor infiltrating immune cells, and tumor DNA&#xD;
           sequence.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        • Ten subjects with lung cancer about to undergo diagnostic/excisional biopsy with the&#xD;
        intent to receive therapy with immune checkpoint inhibitors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the&#xD;
             intent to receive therapy with immune checkpoint inhibitors&#xD;
&#xD;
          -  Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sindhi R, Ashokkumar C, Higgs BW. Cellular alloresponses for rejection-risk assessment after pediatric transplantation. Curr Opin Organ Transplant. 2011 Oct;16(5):515-21. doi: 10.1097/MOT.0b013e32834a94e3. Review.</citation>
    <PMID>21844808</PMID>
  </reference>
  <reference>
    <citation>Ashokkumar C, Talukdar A, Sun Q, Higgs BW, Janosky J, Wilson P, Mazariegos G, Jaffe R, Demetris A, Dobberstein J, Soltys K, Bond G, Thomson AW, Zeevi A, Sindhi R. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant. 2009 Jan;9(1):179-91. doi: 10.1111/j.1600-6143.2008.02459.x. Epub 2008 Oct 31.</citation>
    <PMID>18976293</PMID>
  </reference>
  <reference>
    <citation>Ningappa M, Ashokkumar C, Higgs BW, Sun Q, Jaffe R, Mazariegos G, Li D, Weeks DE, Subramaniam S, Ferrell R, Hakonarson H, Sindhi R. Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection. Am J Transplant. 2016 Feb;16(2):497-508. doi: 10.1111/ajt.13509. Epub 2015 Dec 11.</citation>
    <PMID>26663361</PMID>
  </reference>
  <reference>
    <citation>Ranganathan S, Ningappa M, Ashokkumar C, Higgs BW, Min J, Sun Q, Schmitt L, Subramaniam S, Hakonarson H, Sindhi R. Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma. Sci Rep. 2016 Dec 2;6:38347. doi: 10.1038/srep38347.</citation>
    <PMID>27910913</PMID>
  </reference>
  <reference>
    <citation>Vinayak R, Cruz RJ Jr, Ranganathan S, Mohanka R, Mazariegos G, Soltys K, Bond G, Tadros S, Humar A, Marsh JW, Selby RR, Reyes J, Sun Q, Haberman K, Sindhi R. Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015). Liver Transpl. 2017 Dec;23(12):1577-1588. doi: 10.1002/lt.24847.</citation>
    <PMID>28834194</PMID>
  </reference>
  <reference>
    <citation>Cruz RJ Jr, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw PH, Haberman K, Krishnamurti L, Marsh JW, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery. 2013 Feb;153(2):150-9. doi: 10.1016/j.surg.2012.11.006.</citation>
    <PMID>23331862</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing: The data generated in this study will be available to The Holy Cross Health Institutional Review Board, Inc., Investigators named in this protocol, and Officials of the FDA and HHS. Published information following completion of the study will be provided to study patients.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>24 months</ipd_time_frame>
    <ipd_access_criteria>Upon completion, published results will be provided to participants</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

